Search research articles
Contact Us
Filters
Showing results (561-570 of 577) with videos related to
Page
of 58
Sort By:
Transplantation and Cellular Therapy
|
September 30, 2025
Corrigendum to: Current Activity Trends and Outcomes in Hematopoietic Cell Transplantation and Cellular Therapy - A Report from the CIBMTR, Transplantation and Cellular Therapy, 31:8, August 2025, 505-532; Article Number: JTCT-S-25-00377
Stephen R Spellman, Ke Xu, Temitope Oloyede, et al.
Frontiers in Immunology
|
September 20, 2021
Immune Recovery Following Autologous Hematopoietic Stem Cell Transplantation in HIV-Related Lymphoma Patients on the BMT CTN 0803/AMC 071 Trial
Polina Shindiapina, Maciej Pietrzak, Michal Seweryn, et al.
Blood Advances
|
November 21, 2025
CHARM is Prognostic of Geriatric Morbidity and Toxicity after Allogeneic Transplant for Older Adults: BMT CTN 1704 Study
Andrew S Artz, Brent R Logan, Wael Saber, et al.
Transplantation and Cellular Therapy
|
June 29, 2024
Current Trends and Outcomes in Cellular Therapy Activity in the United States, Including Prospective Patient-Reported Outcomes Data Collection in the Center for International Blood and Marrow Transplant Research Registry
Rachel Cusatis, Carlos Litovich, Zhongyu Feng, et al.
Blood Advances
|
March 18, 2025
Novel Composite Health Assessment Risk Model for Older Allogeneic Transplant Recipients: BMT-CTN 1704
Mohamed L Sorror, Wael Saber, Brent R Logan, et al.
Blood
|
January 8, 2025
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML
Mark J Levis, Mehdi Hamadani, Brent R Logan, et al.
Blood Advances
|
July 1, 2025
Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia
Mark J Levis, Mehdi Hamadani, Brent R Logan, et al.
The New England Journal of Medicine
|
May 11, 2012
Lenalidomide after stem-cell transplantation for multiple myeloma
Philip L McCarthy, Kouros Owzar, Craig C Hofmeister, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 12, 2024
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of <i>FLT3</i>
Mark J Levis, Mehdi Hamadani, Brent Logan, et al.
The Journal of Clinical Investigation
|
June 14, 2016
Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality
Asim Saha, Roddy S O'Connor, Govindarajan Thangavelu, et al.
Page
of 58
Search research articles
Search
Showing results (561-570 of 577) with videos related to
Sort By:
Page
of 58
Transplantation and Cellular Therapy
|
September 30, 2025
Corrigendum to: Current Activity Trends and Outcomes in Hematopoietic Cell Transplantation and Cellular Therapy - A Report from the CIBMTR, Transplantation and Cellular Therapy, 31:8, August 2025, 505-532; Article Number: JTCT-S-25-00377
Stephen R Spellman, Ke Xu, Temitope Oloyede, et al.
Frontiers in Immunology
|
September 20, 2021
Immune Recovery Following Autologous Hematopoietic Stem Cell Transplantation in HIV-Related Lymphoma Patients on the BMT CTN 0803/AMC 071 Trial
Polina Shindiapina, Maciej Pietrzak, Michal Seweryn, et al.
Blood Advances
|
November 21, 2025
CHARM is Prognostic of Geriatric Morbidity and Toxicity after Allogeneic Transplant for Older Adults: BMT CTN 1704 Study
Andrew S Artz, Brent R Logan, Wael Saber, et al.
Transplantation and Cellular Therapy
|
June 29, 2024
Current Trends and Outcomes in Cellular Therapy Activity in the United States, Including Prospective Patient-Reported Outcomes Data Collection in the Center for International Blood and Marrow Transplant Research Registry
Rachel Cusatis, Carlos Litovich, Zhongyu Feng, et al.
Blood Advances
|
March 18, 2025
Novel Composite Health Assessment Risk Model for Older Allogeneic Transplant Recipients: BMT-CTN 1704
Mohamed L Sorror, Wael Saber, Brent R Logan, et al.
Blood
|
January 8, 2025
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML
Mark J Levis, Mehdi Hamadani, Brent R Logan, et al.
Blood Advances
|
July 1, 2025
Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia
Mark J Levis, Mehdi Hamadani, Brent R Logan, et al.
The New England Journal of Medicine
|
May 11, 2012
Lenalidomide after stem-cell transplantation for multiple myeloma
Philip L McCarthy, Kouros Owzar, Craig C Hofmeister, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 12, 2024
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of <i>FLT3</i>
Mark J Levis, Mehdi Hamadani, Brent Logan, et al.
The Journal of Clinical Investigation
|
June 14, 2016
Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality
Asim Saha, Roddy S O'Connor, Govindarajan Thangavelu, et al.
Page
of 58